WASHINGTON (June 20, 2014) The U.S. Food and Drug Administration has approved a new antibiotic from Cubist Pharmaceuticals, Sivextro, to treat serious skin infections often acquired in the hospital.
TheFDA approved Sivextro in both pill form and as an infusible solution for adults with skin infections caused by common bacteria that are often resistant to older antibiotics.
It's the second FDA approval in less than a month for a new antibiotic to treat such infections.
In late May, the FDA approved a similar drug from Durata Therapeutics Inc.
Antibiotics such as penicillin and streptomycin first became widely available in the 1940s, but in recent decades some bacteria have grown resistant to widely used medications.
The overuse and misuse of the drugs by physicians has contributed to the rise of so-called superbugs, experts say.